ARCELLX INC's ticker is and the CUSIP is 03940C100. A total of 140 filers reported holding ARCELLX INC in Q2 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $465,859 | -36.7% | 8,441 | -20.3% | 0.00% | -50.0% |
| Q1 2024 | $736,534 | +40.3% | 10,590 | +12.0% | 0.00% | 0.0% |
| Q4 2023 | $524,976 | +80.8% | 9,459 | +16.9% | 0.00% | +100.0% |
| Q3 2023 | $290,341 | +14.2% | 8,092 | +0.6% | 0.00% | 0.0% |
| Q2 2023 | $254,256 | +26.6% | 8,041 | +23.3% | 0.00% | 0.0% |
| Q1 2023 | $200,881 | -12.7% | 6,520 | -12.3% | 0.00% | 0.0% |
| Q4 2022 | $230,212 | – | 7,431 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 5,500,007 | $170,390,217 | 62.20% |
| PATHWAY CAPITAL MANAGEMENT, LP | 189,120 | $5,858,938 | 10.46% |
| NEA Management Company, LLC | 4,745,262 | $147,008,217 | 8.26% |
| Samsara BioCapital, LLC | 957,451 | $29,661,832 | 6.38% |
| Soleus Capital Management, L.P. | 1,102,447 | $34,153,808 | 4.90% |
| Cormorant Asset Management, LP | 2,075,000 | $64,284 | 4.30% |
| Paradigm Biocapital Advisors LP | 882,101 | $27,327,489 | 3.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,350,333 | $72,813,316 | 3.06% |
| Affinity Asset Advisors, LLC | 240,143 | $7,439,630 | 2.92% |
| CAXTON CORP | 36,302 | $1,124,640 | 2.87% |